Next Up

Tumour Microenvironment: Online

08 March 2022 |

Online: BST (UTC+1)

08 March 2022

Online: BST (UTC+1)

May 2022
May 2022

Immuno UK: In-Person

Designing & delivering innovative immunotherapies to transform cancer care.

06 Sep 2022
Tue, 06 September 2022

Preclinical Immuno-Oncology: Online

Oct 2022
October 2022

Immuno US: In-Person

Discuss the latest strategies to harness the immune system for the development of innovative therapeutics

Highlights

tumour microenvironment
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our first ever Immuno Discussion Group addressing ‘Understanding The Tumour Microenvironment With Advanced Technologies’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
By Tia Byer |
09 December 2021
Tumour Microenvironment
Insight Article
By Tia Byer |
16 Nov 2021
Autoimmunity & Immunology

Insights

Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our first ever Immuno Discussion Group addressing ‘Understanding The Tumour Microenvironment With Advanced Technologies’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
09 December 2021
Insight Article
Tumour associated macrophages are critical drivers in cancer progression and metastasis. Clinical studies now suggest that changing polarisation of macrophages can significantly improve immuno-oncology response. Speaking with senior representatives from Verseau Therapeutics, Pathios Therapeutics, and Faron Pharmaceuticals, we delve into some of the latest techniques in macrophage targeting.
16 November 2021
Commentary
The activation of GPR65 on immune cells by the acidic tumour microenvironment and the resultant immunosuppression may be one of the principal reasons many cancers do not respond to current T Cell checkpoint therapies. Chief Executive Officer Stuart Hughes delves into some of Pathios Therapeutics recent developments in macrophage conditioning and its promise to enable a successful anti-tumour immune response.
01 November 2021
Commentary
At the 2021 Immuno Week: Online event, we sat down with an advisory board comprised of key figures from some of the top biotech companies and research institutions to discuss the acute need for improved combination therapies and predictive biomarkers in immuno-oncology.
22 September 2021

[sponsor section - bespoke content]

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Immuno

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.